Navigation Links
ATS Medical Announces Second Quarter 2009 Earnings Release Date and Conference Call
Date:7/27/2009

MINNEAPOLIS, July 27 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that it will release financial results for the second quarter ended July 4, 2009, after the market close on Monday, August 3, 2009. The Company will host a conference call and webcast on Monday, August 3, 2009 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss its second quarter results and current corporate developments. The dial-in number for the conference call is 866-700-7477 for domestic participants and 617-213-8840 for international participants, with a passcode of 94675879. A live webcast of the call can be accessed at www.atsmedical.com by clicking on the Investors icon.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for seven days. The replay can be accessed by dialing 888-286-8010 for domestic participants and 617-801-6888 for international participants, using the passcode 99143264. The webcast will also be archived on the Company's website.

About ATS Medical

ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site ishttp://www.atsmedical.com.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Midbrook Utilizes Copper in Medical Environments
2. Research Scientist Reports On Time-Tested Solution To Current Medical Crisis
3. Giant Bud Banner Half the Size of Football Field Flies Sunday Protesting Hydroponics Industry Cartel Monopoly that's Harming California's Medical Marijuana Patients
4. Mayor Julian Jolly Reseueollo Dialysis Center Officially Opens Doors With Support From Bridge of Life - DaVita Medical Missions
5. VA Medical Imaging Reaches Record Level
6. UCI Medical Affiliates, Inc.s Internal Investigation Leads to Former Executive Officer Pleading Guilty to Criminal Charges
7. Neusoft Medicals Latest Innovation, NeuViz 16 CT Scanner, Approved by FDA for the U.S. Market
8. U.S. Senator Sherrod Brown to Lend Support at MedWorks Free Medical Clinic This Weekend
9. Healthcare Informatics Associates, an InfoLogix Company, Selected by Hilo Medical Center for MEDITECH 6.0 EMR Implementation
10. Convection Cooled 350-Watt Open Frame Power Supply Meets Medical and Industrial Safety Standards
11. Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer ... resource for fluorescence microscopists and optical system designers, enabling The Right Solution, Right ... the globe, SearchLight has become a tremendously popular tool for the fluorescence imaging ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Journal of ... It can have severe consequences to overall dental health, including complications with speech, eating, ... turn to dental implants to replace lost teeth. As the number of tooth replacements ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Excellence upon National Registry of Emergency Medical Technicians and welcomes this ... said Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: